


CORONA
VIRUS

Clinical Trials

Biomed Industries, Inc. is conducting the following clinical trials:



BIOCOVAX™

Phase 3 Clinical Trials of BioCovax™ for the prophylaxis and treatment of Covid-19

A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for prophylaxis and treatment of early onset of Covid-19

In the Phase 3 clinical trial we will study the safety and efficacy of oral polio vaccine with and without NA-831 versus placebo, with 3,600 participants in many centers in the US, Canada, UK, Australia, New Zealand, China, Vietnam, and Brazil.

BIOMEDIVIR™

Phase 3 Clinical Trials of Biomedivir™ for the prophylaxis and treatment of Covid-19

Biomed has developed Biomedivir™, which is comprised of our neuroprotective agent called NA-831 and Atazanavir. Atazanavir was approved by the FDA for prevention and treatment of HIV/AIDS treatment, and is now a generic drug. Biomedivir™ is an oral formulation which can be used as a prophylaxis and treatment of early onset of Covid-19.

Biomed plans to launch the Phase 2/3 trials of Biomedivir™ for the prophylaxis and treatment of early onset of Covid-19 in early autumn 2020.

NANOMEDIVIR™

Biomed has developed Nanomedivir™, which is comprised of NA-831 and an anti-viral, Remdesivir (made by Gilead Sciences) in nanoparticle-based intranasal formulation. Remdesivir has been granted by the FDA for emergency use of severe cases of Covid-19.

Biomed plan to launch the Phase 1/2 clinical trials of Nanomedivir™ for the prophylaxis and treatment for early and moderate cases of Covid-19 in autumn 2020.

DEXANEUROSONE™

In addition, Biomed has also developed Dexaneurosone™, which is comprised of NA-831 and Dexamethasone in both oral and intranasal formulation. Dexamethasone is an FDA anti-inflammatory drug has been on the market for some 60 years and is used to treat conditions including arthritis and severe asthma. Recent finding that dexamethasone has life-saving potential for severe cases of Covid-19. Our animal studies indicated that a combination of Dexamethasone and NA-831 could be used to prevent and treat early and moderate cases of Covid-19.

Biomed plan to launch the Phase 2/3 clinical trials of Dexaneurosone™ for the prophylaxis and treatment for early and moderate cases of Covid-19 in autumn 2020.

Traneurocin- phase 3 clinical trials

TRANEUROCINE™ (NA-831™)

Phase 3 Clinical Trials of Traneurocin™ (NA-831) for treatment of Alzheimer's Disease

Biomed plans to conduct two Phase 3 clinical trials programs for NA-831:

(1) The COGNITION Program for the treatment of 375 patients with mild and moderate Alzheimer’s disease over 12 months. Age group: 65- 80 years of age.

(2) The PREVENTION Program for the prevention of 550 subjects, asymptomatic from a high risk population over 24 months. Age group: 45-70 years of age.

These trials follow strict scientific standards and regulatory requirements to protect patients and help produce reliable results.

Study physicians will review risks and potential benefits with patients and their caregivers before patients are enrolled in the clinical trials.

The Phase 3 clinical trials have been designed to evaluate its safety and efficacy as required by the US Food and Drug Administration (FDA) and other regulators overseas before being approved for usage and marketing worldwide.

Please contact us **for study locations near you. Contact information is provided so you can reach out to them to find out more and schedule a visit.**